financetom
Business
financetom
/
Business
/
Update: Paladin Energy Drops 8% as It Launches A$300 Million Equity Raising to Fund Patterson Lake South Project
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Paladin Energy Drops 8% as It Launches A$300 Million Equity Raising to Fund Patterson Lake South Project
Sep 16, 2025 9:16 AM

11:33 AM EDT, 09/16/2025 (MT Newswires) -- Paladin Energy ( PALAF ) late Monday said it has launched a fully underwritten equity raising to raise a total of A$300 million.

The equity raising is composed of an A$231 million ASX institutional placement of new Paladin fully paid ordinary shares; a Canadian bought deal private placement to raise C$30 million; and a fully underwritten sale of about A$36 million of existing shares issued and subsequently acquired as a result of the acquisition of Fission Uranium.

Paladin also plans to invite eligible shareholders to participate in a non-underwritten share purchase plan to acquire shares at the same price as the ASX placement and Fission share sale to raise up to an additional A$20 million.

All shares under the ASX placement, Fission share sale and share purchase plan will be issued at a fixed price of A$7.25 per new share, representing an 8% discount to the last close on the ASX on Sept. 15.

Shares issued under the TSX bought deal sale will be issued at a fixed price of C$6.66 per new share.

Proceeds from the equity raising will be used to advance the development of the Patterson Lake South project toward a final investment decision.

The equity raising positions the company with the balance sheet flexibility to progress the Patterson Lake South project alongside the ongoing ramp-up of the Langer Heinrich mine. The project is on track to be completed by the end of fiscal year 2026, and full mining and processing plant operations are planned for fiscal year 2027.

Paladin's share price at last look fell 8% to $6.80 on the TSX in early Tuesday trading.

Price: 6.81, Change: -0.60, Percent Change: -8.04

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alexander's Q3 Adjusted FFO Increases, Revenue Decreases
Alexander's Q3 Adjusted FFO Increases, Revenue Decreases
Nov 3, 2025
09:08 AM EST, 11/03/2025 (MT Newswires) -- Alexander's (ALX) reported Q3 adjusted funds from operations Monday of $2.91 per diluted share, up from $2.84 a year earlier. A single analyst polled by FactSet expected $2.13. Rental revenue for the quarter ended Sept. 30 was $53.4 million, down from $55.7 million a year earlier. A single analyst surveyed by FactSet expected...
Pagaya, Castlelake reach deal for up to $500 million in auto loans
Pagaya, Castlelake reach deal for up to $500 million in auto loans
Nov 3, 2025
WASHINGTON, Nov 3 (Reuters) - Lending platform Pagaya Technologies ( PGY ) on Monday announced an agreement to sell up to $500 million of its auto loans to asset-based private credit manager Castlelake. In a statement, New York City-based Pagaya ( PGY ) said the deal has the potential to significantly accelerate Pagaya's ( PGY ) auto lending platform. The...
Iradimed Q3 Non-GAAP Earnings, Revenue Rise; Q4 Outlook Issued, 2025 Outlook Raised
Iradimed Q3 Non-GAAP Earnings, Revenue Rise; Q4 Outlook Issued, 2025 Outlook Raised
Nov 3, 2025
09:10 AM EST, 11/03/2025 (MT Newswires) -- Iradimed ( IRMD ) reported Q3 non-GAAP earnings Monday of $0.47 per diluted share, up from $0.43 a year earlier. Two analysts polled by FactSet expected $0.46. Revenue for the quarter ended Sept. 30 was $21.2 million, compared with $18.3 million a year earlier. Two analysts surveyed by FactSet expected $20.5 million. The...
Cogent Biosciences posts wider Q3 loss as costs rise
Cogent Biosciences posts wider Q3 loss as costs rise
Nov 3, 2025
Overview * Cogent Biosciences ( COGT ) reports Q3 net loss of $80.9 mln, up from $70.6 mln in 2024 * Cash position of $390.9 mln expected to fund operations through 2027 * Upcoming PEAK and APEX trial results expected in Nov and Dec 2025 Outlook * Cogent plans to announce PEAK trial results in November 2025 * Company expects...
Copyright 2023-2026 - www.financetom.com All Rights Reserved